Eledon Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript
Good morning, and welcome to the 2023 Jefferies Global Healthcare Conference. My name is Dominick Tocci with the Jefferies Investment Banking team. And it is my great pleasure to introduce to you, DA Gros, CEO of Eledon Pharmaceuticals.
Thank you, Dominic, and thank you to Jefferies for having us today. I'll be making forward-looking statements. And so I encourage everyone to look at our forward-looking statement and disclosures.
Eledon is a biotech that is focused on the development of immunological and specifically anti-CD40, anti-CD40 ligand therapeutics. Our lead asset is tegoprubart, which is currently in Phase 2, and it's a molecule that we've now had in over 100 human subjects and of which we've shown, in prior studies, a very clear target engagement as well as our ability to decrease a broad range of biomarkers. From a capital perspective, we are in a strong position. We recently raised the money in a tranched raise, and using
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |